Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
6.14 EUR | +3.02% | -5.83% | -4.66% |
Apr. 17 | Orapi SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 12 | Orapi: Groupe Paredes holds almost 90% of the capital | CF |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The stock, which is currently worth 2024 to 0.41 times its sales, is clearly overvalued in comparison with peers.
- The opinion of analysts covering the stock has improved over the past four months.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is in debt and has limited leeway for investment
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Commodity Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-4.66% | 41.45M | - | ||
+5.67% | 103B | A- | ||
-1.80% | 65.6B | A- | ||
+39.52% | 39.06B | B | ||
+12.91% | 37.58B | B | ||
+7.41% | 33.26B | A- | ||
+6.85% | 19.22B | B- | ||
+12.86% | 16.83B | C+ | ||
+7.73% | 15.03B | B | ||
+16.93% | 14.96B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ORAP Stock
- Ratings ORAPI